The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
By 2030, How Much Growth In Market Size Is Expected For The Sotrovimab Or Xevudy Market?
The expansion witnessed in the historical period was primarily due to the urgent approval of COVID-19 monoclonal antibodies, the significant risk of hospitalization in the early stages of the pandemic, the rapid rollout of antibody therapies, governmental acquisition of antiviral treatments, and the growth of infrastructure for infusion-based care.
The expansion anticipated during the forecast period is due to the development of antibody treatments resilient to variants, an increasing emphasis on readiness for future global health crises, heightened funding for biological antiviral agents, the broadening availability of infusion services in outpatient settings, and the incorporation of monoclonal antibody treatments into routine medical procedures.
Key developments expected in the forecast period encompass the escalating application of monoclonal antibody treatments, a heightened concentration on treating viral infections in their initial phases, the proliferation of specific antiviral biological products, an increasing prioritization of safeguarding vulnerable patients, and the accelerated creation of medicines designed for pandemic response.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20383&type=smp
What Key Growth Drivers Are Influencing The Sotrovimab Or Xevudy Market?
The increasing number of COVID-19 infections is projected to fuel the expansion of the sotrovimab or xevudy market in the future. COVID-19, an illness stemming from the SARS-CoV-2 virus, disseminates via respiratory droplets, leading to symptoms ranging from slight fever to critical respiratory problems. Preventative measures include vaccinations and good hygiene practices. The escalating number of COVID-19 cases can be attributed to elements like novel variants, diminishing immunity, relaxed public health mandates, colder season indoor social events, and inconsistent vaccine distribution. Sotrovimab offers treatment for high-risk COVID-19 patients by neutralizing the virus in its early stages, thereby averting serious consequences such as hospital admission or fatality. For example, data from March 2023, released by the Office for National Statistics, a UK government department for official statistics, indicated that approximately 1.9 million individuals in the UK (2.9% of the population) had COVID at that time. A significant majority (92%) had contracted COVID-19 more than 12 weeks prior, with 69% enduring symptoms for over a year and 41% for over two years. Consequently, the growing incidence of COVID cases is set to propel the growth of the sotrovimab or xevudy market.
What Are The Core Segment Classifications In The Sotrovimab Or Xevudy Market?
The sotrovimab or xevudy market covered in this report is segmented –
1) By Indication: COVID-19 Early Treatment, Post-Exposure Prophylaxis
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By End User: Pediatric, Adult, Geriatric
Which Companies Are Influencing The Sotrovimab Or Xevudy Market?
Major companies operating in the sotrovimab or xevudy market are GSK plc, Vir Biotechnology Inc.
Access The Complete Sotrovimab Or Xevudy Market Report:
https://www.thebusinessresearchcompany.com/report/sotrovimab-or-xevudy-global-market-report
Which Region Contributes The Most To The Sotrovimab Or Xevudy Market?
North America was the largest region in the sotrovimab or xevudy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sotrovimab or xevudy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model